Allarity Therapeutics Inc (FRA:C6D0) Stock News, Headlines & Updates
Allarity Therapeutics Inc Stock News from GuruFocus
- 1
Jun 27, 2024
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Marketwired • 7:00am
Jun 25, 2024
Allarity Therapeutics' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Marketwired • 7:00am
May 20, 2024
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Marketwired • 7:00am
May 07, 2024
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Marketwired • 9:00am
May 06, 2024
Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
Marketwired • 7:00am
May 02, 2024
Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Marketwired • 7:00am
Apr 29, 2024
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Marketwired • 6:00am
Apr 17, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news